These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36062503)

  • 1. Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
    Gao G; Cui L; Zhou F; Jiang T; Wang W; Mao S; Wu F; Jiang F; Zhang B; Bei T; Xie W; Zhang C; Zhang H; Gao C; Zhao X; Bai Y; Zhou C; Ren S
    Int J Cancer; 2023 Jan; 152(1):79-89. PubMed ID: 36062503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
    Wang L; Ren Z; Yu B; Tang J
    J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
    Hu X; Guo J; Shi J; Li D; Li X; Zhao W
    BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
    Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
    Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.
    Shang X; Zhang W; Han W; Xia H; Liu N; Wang X; Liu Y
    BMC Pulm Med; 2023 Nov; 23(1):482. PubMed ID: 38031067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S
    Front Immunol; 2022; 13():955800. PubMed ID: 36405701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
    Alessi JV; Wang X; Elkrief A; Ricciuti B; Li YY; Gupta H; Spurr LF; Rizvi H; Luo J; Pecci F; Lamberti G; Recondo G; Venkatraman D; Di Federico A; Gandhi MM; Vaz VR; Nishino M; Sholl LM; Cherniack AD; Ladanyi M; Price A; Richards AL; Donoghue M; Lindsay J; Sharma B; Turner MM; Pfaff KL; Felt KD; Rodig SJ; Lin X; Meyerson ML; Johnson BE; Christiani DC; Schoenfeld AJ; Awad MM
    J Thorac Oncol; 2023 Nov; 18(11):1524-1537. PubMed ID: 37247843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
    Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
    Front Immunol; 2022; 13():991091. PubMed ID: 36248841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
    Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of
    Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
    JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
    Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.